Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 3/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2562987 | 0.90 | PDE10A (0.44) | PDE4BPDE4DPDE4APDE4CPDE10A | |
| SCHEMBL2571325 | 0.89 | PDE4A (0.43) | PDE4BPDE4DPDE4APDE4CPDE10A | |
| SCHEMBL2560888 | 0.89 | PDE10A (0.48) | PDE4BPDE4DPDE4APDE4CPDE10A | |
| SCHEMBL2556888 | 0.89 | PDE10A (0.48) | PDE4BPDE4DPDE4APDE4CPDE10A | |
| SCHEMBL2577646 | 0.88 | PDE10A (0.47) | PDE4BPDE4DPDE4APDE4CPDE10A | |
| SCHEMBL2556896 | 0.88 | PDE10A (0.49) | PDE4BPDE4DPDE4APDE4CPDE10A | |
| SCHEMBL2560140 | 0.88 | PDE10A (0.47) | PDE4BPDE4DPDE4APDE4CPDE10A | |
| SCHEMBL2563217 | 0.87 | PDE10A (0.49) | PDE4BPDE4DPDE4APDE4CPDE10A | |
| SCHEMBL2562898 | 0.86 | PDE10A (0.46) | PDE4BPDE4DPDE4APDE4CPDE10A | |
| SCHEMBL2576250 | 0.86 | PDE10A (0.46) | PDE4BPDE4DPDE4APDE4CPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011132051-A2 | TRICYCLE COMPOUNDS AS PHOSPHODIESTERASE-10 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2011-10-27 | — | — | WO | disclosed |